Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Japanese advisory committee recommends approval of class III antiarrhythmic

June 8, 1999

Patient treatment completed in pivotal ranolazine trial in angina

June 7, 1999

Pfizer claims PDE1 inhibitors for range of cardiovascular and other disorders

June 7, 1999

First European launch for Tanatril

June 4, 1999

DHA and EPA have differential effects on ambulatory BP and HR in humans

June 2, 1999

Spray formulation of isosorbide dinitrate superior to tablet formulation in hypertensive emergencies

June 2, 1999

Plant-derived compounds significantly reduce BP in hypertensive patients, SHRs

June 1, 1999

CGRP gene transfer successful and effective in rat model of pulmonary hypertension

June 1, 1999

Novel class III antiarrhythmic agents synthesized at Merck

June 1, 1999

Chinese scientists present new antiarrhythmic agent and effects on ischemia/reperfusion injury

June 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...